Skip to content
RKWD
ROCKWOOD RESEARCH · A CORPORATE FILINGS WEBSITE|STRAIGHT FROM THE SOURCE · SEC EDGAR|SPONSOREDYour message on this tape — bid on the Rockwood Ad Exchange · Rockwood Ad Exchange|
Rockwood Research
…

RLMD

RELMADA THERAPEUTICS, INC.

Pharmaceutical Preparations · SIC 2834CIK 1553643Held by 3 tracked managersEDGAR filings ↗10-K/10-Q ↗

SHARE:XLINKEDINEMAIL
Revenue FY2025
—
Net Income FY2025
$(57.0M)
EPS (Basic, as reported)
$-1.45
Net Margin FY2025
—
ROE FY2025
-66.3%
Total Equity
$87.0M
Shares Out
107M
Business description

RELMADA THERAPEUTICS, INC. — Pharmaceutical Preparations. Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2012–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions
i
default rows · click any row to chart itNet income: (3) → (57)
Fiscal yearFY2016FY2017FY2018FY2019FY2020FY2021⚑FY2022FY2023FY2024FY2025
Revenue——————————
Cost of revenue——————————
Gross profit——————————
Research & development(6)(1)(3)(7)(36)(91)(113)(55)(46)(27)
General & administrative(10)(6)(4)(6)(25)(35)(48)(49)(38)(32)
Total operating expenses(16)(7)(7)(13)(61)(126)(161)(104)(84)(59)
Operating income(16)(7)(7)(13)(61)(126)(161)(104)(84)(59)
Interest expense——————————
Interest & investment income———————541
Other income (expense), net131(2)(5)104542
Net income(3)(6)(9)(17)(59)(126)(157)(99)(80)(57)
EPS — basic—————($7.16)($5.30)($3.28)($2.65)($1.45)
EPS — diluted—————($7.16)($5.30)($3.28)($2.65)($1.45)
Shares outstanding — basic (M)—————1830303039
Shares outstanding — diluted (M)—————1830303039

Showing the latest 10 of 14 fiscal years.

  • ⚑ Weighted-average shares changed ×1.67 between FY2021 and FY2022 — a large issuance or reduction. Per-share figures on either side are as reported and not adjusted.

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.